Myopenia and Mechanism of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study (WF-1806)

For a patient to be eligible for participation in this study, all of the following criteria must apply.

• Newly diagnosed metastatic CRC or metastatic recurrence of CRC greater than 1 year from diagnosis at age >= 65y.
• Planning to undergo 1st line 5-FU based chemotherapy (as monotherapy [as 5-FU alone or capecitabine] or in combination with oxaliplatin and/or irinotecan +/- biologics).
• Estimated life expectancy >= 6 months.
• Patients must be able to read and comprehend English (for questionnaire completion).
• Ability to understand and the willingness to sign a written informed consent document.
• Patient eligibility is not dependent on BMI or weight. Patients with a significant (+- > 10%) body weight change in the previous 12 months are eligible for this study.

A patient will not be eligible for participation in this study if any of the following criteria apply.

• Patients enrolled on hospice.
• Prior systemic chemotherapy for metastatic colorectal cancer (ok if adjuvant chemotherapy completed >= 12 months prior to disease recurrence).
• Patients may not be receiving any other investigational agents.
• No untreated brain metastases. Patients with treated brain metastases are eligible.

To learn more, visit ClinicalTrials.Gov

Study Type

Observational

Principal Investigator(s)

James Bearden III, MD

Sponsor(s)

Wake Forest University Health Sciences